ERBB2 and acute lymphoblastic leukemia: As lapatinib and imatinib/nilotinib are FDA-approved for use in various cancer types, our data suggest a clinical opportunity for the personalization of therapy for the subset of Ph+ALL patients that exhibit ErbB2 expression.